Added to YB: 2025-02-18
Pitch date: 2025-01-01
CATX [bullish]
Perspective Therapeutics, Inc.
-17.59%
current return
Author Info
No bio for this author
Company Info
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
$177.0M
Pitch Price
$3.24
Price Target
21.00 (+687%)
Dividend
N/A
EV/EBITDA
0.43
P/E
-1.98
EV/Sales
-21.01
Sector
Biotechnology
Category
special_situation
Perspective Therapeutics, Inc. - $CATX
CATX: Negative EV radiopharma biotech with 4-5x+ upside. Promising drugs/platform in hot M&A space. Recent trial disappointing due to underdosing, but fixable. Lead isotope PB-212 easier to manufacture/administer. $267M cash runway to mid-2026. Takeout potential at $1bn+ like peers. Catalysts: M&A, trial progress, FDA updates.
Read full article (11 min)